Indivior (LON:INDV) Receives Buy Rating from Jefferies Financial Group

Indivior (LON:INDV - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Jefferies Financial Group in a report issued on Tuesday, Marketbeat reports. They presently have a GBX 1,800 ($22.84) target price on the specialty pharmaceutical company's stock. Jefferies Financial Group's target price would indicate a potential upside of 94.74% from the stock's current price.

Separately, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,500 ($19.03) price objective on shares of Indivior in a research report on Thursday, September 5th.

Indivior Price Performance

INDV stock traded down GBX 25.68 ($0.33) during midday trading on Tuesday, hitting GBX 924.32 ($11.73). 325,897 shares of the stock were exchanged, compared to its average volume of 1,124,116. The stock's 50-day moving average price is GBX 768.84 and its 200-day moving average price is GBX 923.78. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.85. The stock has a market cap of £1.19 billion, a price-to-earnings ratio of -1,155.41, a PEG ratio of -5.57 and a beta of 0.19. Indivior has a fifty-two week low of GBX 554.50 ($7.04) and a fifty-two week high of GBX 1,770 ($22.46).

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.